Action REPL REPLIMUNE GROUP, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Replimune Group, Inc.

Actions

REPL

US76029N1063

Temps réel estimé Cboe BZX
Autres places de cotation
 21:52:05 28/06/2024 		Varia. 5j. Varia. 1 janv.
8,955 USD +5,11% Graphique intraday de Replimune Group, Inc. +4,94% +5,81%
13/06 Replimune Group signe un accord de PIPE de 100 millions de dollars avec des investisseurs institutionnels MT
07/06 REPLIMUNE GROUP, INC. : HC Wainwright réitère son opinion positive sur le titre ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index
Replimune Group Signs $100 Million PIPE Deal with Institutional Investors
Replimune Announces $100 Million Private Placement Financing
Replimune : Corporate Presentation June 2024
Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
Sector Update: Health Care
Replimune Shares Rise as Study Data on Melanoma Treatment Improves
Replimune : Primary Analysis of the IGNYTE Registrational Cohort Presentation June 2024
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma
Replimune : IGNYTE Oral Presentation at ASCO 2024
Replimune : RP2 Uveal Melanoma Oral Presentation at ASCO 2024
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology Annual Meeting
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
Replimune : Corporate Presentation May 2024
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action REPL
  4. Actualités Replimune Group, Inc.
  5. Autres langues